董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Shannon Hall | 女 | Director | 56 | 25.00万美元 | 0.42 | 2026-09-08 |
| Jennifer Alltoft | 女 | Director | 58 | 26.00万美元 | 0.49 | 2026-09-08 |
| Shannon Hall | 女 | Director | 57 | 未披露 | 未持股 | 2026-09-08 |
| R. Tony Tripeny | 男 | Director | 67 | 26.00万美元 | 0.54 | 2026-09-08 |
| Shiraz Ladiwala | 男 | Independent Director and Lead Independent Director | 60 | 26.00万美元 | 0.85 | 2026-09-08 |
| Mark Capone | 男 | Director | 64 | 26.00万美元 | 0.34 | 2026-09-08 |
| Siddhartha Kadia | 男 | Chief Executive Officer and Director and President | 57 | 未披露 | 未持股 | 2026-09-08 |
| Siddhartha Kadia | 男 | Chief Executive Officer and Director and President | 56 | 未披露 | 未持股 | 2026-09-08 |
| John Sullivan | 男 | Chairperson of the Board and Director | 73 | 29.50万美元 | 7.01 | 2026-09-08 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Brian Archbold | 男 | Senior Vice President of Continuous Improvement | 51 | 218.25万美元 | 1.85 | 2026-09-08 |
| Siddhartha Kadia | 男 | Chief Executive Officer and Director and President | 57 | 未披露 | 未持股 | 2026-09-08 |
| Siddhartha Kadia | 男 | Chief Executive Officer and Director and President | 56 | 未披露 | 未持股 | 2026-09-08 |
| John V. Sakys | 男 | Chief Financial Officer and Vice President | 58 | 247.15万美元 | 3.77 | 2026-09-08 |
董事简历
中英对照 | 中文 | 英文- Shannon Hall
-
Shannon Hall2014年10月被任命为Life Science Group的执行副总裁兼总裁。之前，2008年至2014年她是Life Science Group实验室分离事业部的副总裁兼总经理在此之前，自1992年加入Bio-Rad公司，她曾在Life Science Group担任各种职位，包括每个实验室分离部和基因表达部的部门营销经理；分子生物学事业部的业务部市场营销经理以及一些产品经理。
Shannon Hall was appointed Executive Vice President, President, Life Science Group in October 2014. Previously, she was Vice President and General Manager of the Laboratory Separations Division, Life Science Group from 2008 to 2014. Prior to that, she held various positions within Life Science Group since joining Bio-Rad in 1992 including Division Marketing Manager of each of the Laboratory Separations Division and Gene Expression Division, Business Unit Marketing Manager of the Molecular Biology Business Unit, as well as several product manager positions. - Shannon Hall2014年10月被任命为Life Science Group的执行副总裁兼总裁。之前，2008年至2014年她是Life Science Group实验室分离事业部的副总裁兼总经理在此之前，自1992年加入Bio-Rad公司，她曾在Life Science Group担任各种职位，包括每个实验室分离部和基因表达部的部门营销经理；分子生物学事业部的业务部市场营销经理以及一些产品经理。
- Shannon Hall was appointed Executive Vice President, President, Life Science Group in October 2014. Previously, she was Vice President and General Manager of the Laboratory Separations Division, Life Science Group from 2008 to 2014. Prior to that, she held various positions within Life Science Group since joining Bio-Rad in 1992 including Division Marketing Manager of each of the Laboratory Separations Division and Gene Expression Division, Business Unit Marketing Manager of the Molecular Biology Business Unit, as well as several product manager positions.
- Jennifer Alltoft
-
Jennifer Alltoft，她在Pfizer， Inc.拥有32年的职业生涯，在那里她担任研发，销售和营销以及一般管理的多个职位，包括辉瑞公司生物仿制药部门的全球领导（2019年）。Alltoft女士从2021年到2023年6月领导Sumitovant Biopharma的业务开发和商业化，目前是Sumitomo Pharma America的商业战略和市场开发主管。Alltoft女士于1989年获得Bromley College的高级国家应用生物学证书，并于1992年获得North East Surrey College of Technology的生物科学学士学位。
Jennifer Alltoft,had a 32-year career at Pfizer, Inc., where she held multiple positions in Research and Development, Sales and Marketing, and General Management, including Global Leadership of Pfizer Inc.'s Biosimilar Division during 2019. Ms. Alltoft led Business Development and Commercialization at Sumitovant Biopharma from 2021 to June 2023 and is currently Head of Commercial Strategy and Market Development for Sumitomo Pharma America. Ms. Alltoft received a Higher National Certificate in Applied Biology from Bromley College in 1989, and a Bachelor of Science degree in Biological Sciences from North East Surrey College of Technology in 1992. - Jennifer Alltoft，她在Pfizer， Inc.拥有32年的职业生涯，在那里她担任研发，销售和营销以及一般管理的多个职位，包括辉瑞公司生物仿制药部门的全球领导（2019年）。Alltoft女士从2021年到2023年6月领导Sumitovant Biopharma的业务开发和商业化，目前是Sumitomo Pharma America的商业战略和市场开发主管。Alltoft女士于1989年获得Bromley College的高级国家应用生物学证书，并于1992年获得North East Surrey College of Technology的生物科学学士学位。
- Jennifer Alltoft,had a 32-year career at Pfizer, Inc., where she held multiple positions in Research and Development, Sales and Marketing, and General Management, including Global Leadership of Pfizer Inc.'s Biosimilar Division during 2019. Ms. Alltoft led Business Development and Commercialization at Sumitovant Biopharma from 2021 to June 2023 and is currently Head of Commercial Strategy and Market Development for Sumitomo Pharma America. Ms. Alltoft received a Higher National Certificate in Applied Biology from Bromley College in 1989, and a Bachelor of Science degree in Biological Sciences from North East Surrey College of Technology in 1992.
- Shannon Hall
-
Shannon M.Hall于2020年5月11日被任命为董事。Hall女士目前在一家私人控股公司的董事会任职。此外，她曾担任多个早期初创公司（主要是生命科学行业）的投资者和顾问，也是Pow.Bio公司的共同创始人。25年来，她曾任职Bio-Rad Laboratories公司，担任进步职务，包括担任执行领导职务10年以上。她曾领导Bio-Rad Laboratories公司的核心业务，创立有效的领导团队，并改善她的组织的销售增长和利润率。Hall女士在圣本笃学院（College of Saint Benedict）获得生物学文学学士学位。
Shannon Hall,currently serves on the Board of one privately held company. Additionally, she has worked as an investor and advisor to multiple early-stage startups, primarily in the life sciences industry since 2018, and she co-founded Pow. Bio in 2019. For 25 years, she worked at Bio-Rad Laboratories in progressive roles, including over ten years in executive leadership roles.Ms. Hall received a Bachelor of Arts in Biology from the College of Saint Benedict. - Shannon M.Hall于2020年5月11日被任命为董事。Hall女士目前在一家私人控股公司的董事会任职。此外，她曾担任多个早期初创公司（主要是生命科学行业）的投资者和顾问，也是Pow.Bio公司的共同创始人。25年来，她曾任职Bio-Rad Laboratories公司，担任进步职务，包括担任执行领导职务10年以上。她曾领导Bio-Rad Laboratories公司的核心业务，创立有效的领导团队，并改善她的组织的销售增长和利润率。Hall女士在圣本笃学院（College of Saint Benedict）获得生物学文学学士学位。
- Shannon Hall,currently serves on the Board of one privately held company. Additionally, she has worked as an investor and advisor to multiple early-stage startups, primarily in the life sciences industry since 2018, and she co-founded Pow. Bio in 2019. For 25 years, she worked at Bio-Rad Laboratories in progressive roles, including over ten years in executive leadership roles.Ms. Hall received a Bachelor of Arts in Biology from the College of Saint Benedict.
- R. Tony Tripeny
-
R. Tony Tripeny，自2023年5月1日起担任Origin公司董事会成员，并于2023年5月2日被任命为审计委员会主席。他将在公司2023年年会上竞选连任。自2022年以来，他一直担任Mesa Laboratories, Inc.（生命科学工具和关键质量控制解决方案的设计和制造的全球领导者）的董事。在Corning（全球领先的材料科学创新者）的职业生涯中，Tripeny先生在公司会计和财务领域担任各种进步的领导职务，包括执行副总裁、首席财务官（2015年9月至2022年2月）和高级副总裁、公司财务总监兼首席会计官（2009年4月至2015年8月）。2012年2月至2018年5月，他还担任跨国机床制造商Hardinge Inc.的董事会成员；1981年至1985年，他担任汽车技术公司GKN Automotive Inc.的金融分析师。Tripeny先生拥有宾夕法尼亚大学沃顿商学院的经济学学位，是金融高管协会和管理会计协会的成员。
R. Tony Tripeny has served as Chair of Origin's board of directors since March 2024, and has served as a member of Origin's board of directors since May 1, 2023. Previously, from May 1, 2023 through March 1, 2024, Mr. Tripeny also served as Chair of the Audit Committee.Since 2022, he has served as a director at Mesa Laboratories, Inc., a global leader in the design and manufacturing of life science tools and critical quality control solutions. Mr. Tripeny has been a director at IperionX Ltd., a titanium metal and critical materials company, since March 2025. He also served on the board of Hardinge Inc., a multi national machine tool builder, from February 2012 to May 2018. During his 37 year career with Corning, Incorporated, a global leading innovator in materials science, Mr. Tripeny held various, progressive leadership roles in the areas of corporate accounting and finance, including Executive Vice President, Chief Financial Officer from September 2015 to February 2022 and Senior Vice President, Corporate Controller and Principal Accounting Officer from April 2009 to August 2015. Prior to joining Corning, Mr. Tripeny served as a Financial Analyst for GKN Automotive Inc., an automotive technology company, from 1981 to 1985. Mr. Tripeny holds an economics degree from the University of Pennsylvania's Wharton School of Business. - R. Tony Tripeny，自2023年5月1日起担任Origin公司董事会成员，并于2023年5月2日被任命为审计委员会主席。他将在公司2023年年会上竞选连任。自2022年以来，他一直担任Mesa Laboratories, Inc.（生命科学工具和关键质量控制解决方案的设计和制造的全球领导者）的董事。在Corning（全球领先的材料科学创新者）的职业生涯中，Tripeny先生在公司会计和财务领域担任各种进步的领导职务，包括执行副总裁、首席财务官（2015年9月至2022年2月）和高级副总裁、公司财务总监兼首席会计官（2009年4月至2015年8月）。2012年2月至2018年5月，他还担任跨国机床制造商Hardinge Inc.的董事会成员；1981年至1985年，他担任汽车技术公司GKN Automotive Inc.的金融分析师。Tripeny先生拥有宾夕法尼亚大学沃顿商学院的经济学学位，是金融高管协会和管理会计协会的成员。
- R. Tony Tripeny has served as Chair of Origin's board of directors since March 2024, and has served as a member of Origin's board of directors since May 1, 2023. Previously, from May 1, 2023 through March 1, 2024, Mr. Tripeny also served as Chair of the Audit Committee.Since 2022, he has served as a director at Mesa Laboratories, Inc., a global leader in the design and manufacturing of life science tools and critical quality control solutions. Mr. Tripeny has been a director at IperionX Ltd., a titanium metal and critical materials company, since March 2025. He also served on the board of Hardinge Inc., a multi national machine tool builder, from February 2012 to May 2018. During his 37 year career with Corning, Incorporated, a global leading innovator in materials science, Mr. Tripeny held various, progressive leadership roles in the areas of corporate accounting and finance, including Executive Vice President, Chief Financial Officer from September 2015 to February 2022 and Senior Vice President, Corporate Controller and Principal Accounting Officer from April 2009 to August 2015. Prior to joining Corning, Mr. Tripeny served as a Financial Analyst for GKN Automotive Inc., an automotive technology company, from 1981 to 1985. Mr. Tripeny holds an economics degree from the University of Pennsylvania's Wharton School of Business.
- Shiraz Ladiwala
-
Shiraz S. Ladiwala，在赛默飞世尔 24年的职业生涯中，Ladiwala先生在公司战略、发展和业务运营领域担任过各种进步的领导角色，包括战略和公司发展高级副总裁和亚太区总经理。他在孟买大学获得商学学士学位，在密歇根大学罗斯商学院获得工商管理硕士学位。
Shiraz Ladiwala,During his 24-year career with Thermo Fisher Scientific, Mr. Ladiwala held various progressive leadership roles in the areas of corporate strategy and development and business operations, including as Senior Vice President of Strategy and Corporate Development and General Manager of Asia-Pacific. He received a bachelor's degree in commerce from the University of Bombay and a Master of Business Administration from the University of Michigan Ross School of Business. - Shiraz S. Ladiwala，在赛默飞世尔 24年的职业生涯中，Ladiwala先生在公司战略、发展和业务运营领域担任过各种进步的领导角色，包括战略和公司发展高级副总裁和亚太区总经理。他在孟买大学获得商学学士学位，在密歇根大学罗斯商学院获得工商管理硕士学位。
- Shiraz Ladiwala,During his 24-year career with Thermo Fisher Scientific, Mr. Ladiwala held various progressive leadership roles in the areas of corporate strategy and development and business operations, including as Senior Vice President of Strategy and Corporate Development and General Manager of Asia-Pacific. He received a bachelor's degree in commerce from the University of Bombay and a Master of Business Administration from the University of Michigan Ross School of Business.
- Mark Capone
-
马克·卡彭，是一位成就卓著的生命科学CEO，在分子诊断、遗传学、生物技术、医疗设备和制药领域拥有近40年的经验。自2020年3月起，他担任生物制药组织咨询公司Precision Medicine Advisors，LLC的首席执行官。此前，他担任了5年的万基遗传 CEO，将公司从1400万美元的营收、150名员工、一个产品转变为8.5亿美元营收、3000名员工、11个产品的全球精准医疗领导者，其中四个产品是通过超10亿美元的资本投资获得的。在加入万基遗传之前，Capone先生曾在礼来公司担任过多个职务，包括销售总监、厂长、研发组长、生化工程师。他拥有麻省理工学院斯隆管理学院管理学硕士学位、麻省理工学院（生物）化学工程学硕士学位、宾夕法尼亚州立大学化学工程学学士学位，以最高荣誉毕业。此外，卡彭先生还担任两家私营公司的非执行董事。
Mark Capone,is an accomplished life sciences CEO with nearly 40 years of experience in molecular diagnostics, genetics, biotechnology, medical devices, and pharmaceuticals. Since March 2020, he has served as the CEO of Precision Medicine Advisors, LLC, a consulting firm for biopharmaceutical organizations. Previously, he was the CEO of Myriad Genetics for five years, where he transformed the company from $14 million in revenue, 150 employees, and one product to a global leader in precision medicine with $850 million in revenue, 3,000 employees, and 11 products, four of which were acquired through over $1 billion in capital investments. Before Myriad Genetics, Mr. Capone held various roles at Eli Lilly and Company, including Sales Director, Plant Manager, R&D Team Leader, and Biochemical Engineer. He holds an MS in Management from the MIT Sloan School of Management, an MS in (Bio) Chemical Engineering from MIT, and a BS in Chemical Engineering from Penn State, graduating with highest distinction. Additionally, Mr. Capone serves as a non-executive director for two privately held companies. - 马克·卡彭，是一位成就卓著的生命科学CEO，在分子诊断、遗传学、生物技术、医疗设备和制药领域拥有近40年的经验。自2020年3月起，他担任生物制药组织咨询公司Precision Medicine Advisors，LLC的首席执行官。此前，他担任了5年的万基遗传 CEO，将公司从1400万美元的营收、150名员工、一个产品转变为8.5亿美元营收、3000名员工、11个产品的全球精准医疗领导者，其中四个产品是通过超10亿美元的资本投资获得的。在加入万基遗传之前，Capone先生曾在礼来公司担任过多个职务，包括销售总监、厂长、研发组长、生化工程师。他拥有麻省理工学院斯隆管理学院管理学硕士学位、麻省理工学院（生物）化学工程学硕士学位、宾夕法尼亚州立大学化学工程学学士学位，以最高荣誉毕业。此外，卡彭先生还担任两家私营公司的非执行董事。
- Mark Capone,is an accomplished life sciences CEO with nearly 40 years of experience in molecular diagnostics, genetics, biotechnology, medical devices, and pharmaceuticals. Since March 2020, he has served as the CEO of Precision Medicine Advisors, LLC, a consulting firm for biopharmaceutical organizations. Previously, he was the CEO of Myriad Genetics for five years, where he transformed the company from $14 million in revenue, 150 employees, and one product to a global leader in precision medicine with $850 million in revenue, 3,000 employees, and 11 products, four of which were acquired through over $1 billion in capital investments. Before Myriad Genetics, Mr. Capone held various roles at Eli Lilly and Company, including Sales Director, Plant Manager, R&D Team Leader, and Biochemical Engineer. He holds an MS in Management from the MIT Sloan School of Management, an MS in (Bio) Chemical Engineering from MIT, and a BS in Chemical Engineering from Penn State, graduating with highest distinction. Additionally, Mr. Capone serves as a non-executive director for two privately held companies.
- Siddhartha Kadia
-
Siddhartha Kadia是一位经验丰富的高管，在生命科学、诊断和生物技术领域拥有超过20年的经验。自2025年1月起，Kadia博士担任Calibre Scientific的首席执行官，Calibre Scientific是一家为实验室研究、诊断和生物制药界提供生命科学试剂、工具、仪器和其他耗材的多元化全球供应商。2022年3月至2023年8月，担任PhenomeX及其前身Berkeley Lights的首席执行官，直至其被Bruker Corporation收购。2014年至2018年，任EAG实验室首席执行官。2005年至2014年，他曾在Life Technologies（前身为Invitrogen Corporation）担任多个职务，包括该公司生命科学部门总裁，直到该公司被赛默飞世尔收购。Kadia博士的职业生涯始于咨询公司麦肯锡公司，他曾于2001年至2005年在该公司工作。Kadia博士拥有约翰霍普金斯大学医学院的生物医学工程博士学位，在那里他获得了David Israel Macht研究卓越奖，以及罗格斯大学的生物医学工程理学硕士学位。
Siddhartha Kadia is an experienced executive with over 20 years in the life sciences, diagnostics and biotechnology sectors. Since January 2025, Dr. Kadia has served as Chief Executive Officer of Calibre Scientific, a diversified global provider of life science reagents, tools, instruments, and other consumables to the lab research, diagnostics and biopharmaceutical communities. From March 2022 to August 2023, he served as Chief Executive Officer of PhenomeX and its predecessor Berkeley Lights until its acquisition by Bruker Corporation. From 2014 to 2018, he served as Chief Executive Officer of EAG Laboratories. From 2005 to 2014, he served in various roles at Life Technologies (formerly Invitrogen Corporation), including President of the company’s Life Sciences Division, until the company was acquired by Thermo Fisher Scientific. Dr. Kadia began his career at consultancy firm McKinsey & Company, where he worked from 2001 to 2005. Dr. Kadia holds a Ph.D. in Biomedical Engineering from Johns Hopkins University School of Medicine, where he was honored with the David Israel Macht Award for Excellence in Research, and a Masters of Science in Biomedical Engineering from Rutgers University. - Siddhartha Kadia是一位经验丰富的高管，在生命科学、诊断和生物技术领域拥有超过20年的经验。自2025年1月起，Kadia博士担任Calibre Scientific的首席执行官，Calibre Scientific是一家为实验室研究、诊断和生物制药界提供生命科学试剂、工具、仪器和其他耗材的多元化全球供应商。2022年3月至2023年8月，担任PhenomeX及其前身Berkeley Lights的首席执行官，直至其被Bruker Corporation收购。2014年至2018年，任EAG实验室首席执行官。2005年至2014年，他曾在Life Technologies（前身为Invitrogen Corporation）担任多个职务，包括该公司生命科学部门总裁，直到该公司被赛默飞世尔收购。Kadia博士的职业生涯始于咨询公司麦肯锡公司，他曾于2001年至2005年在该公司工作。Kadia博士拥有约翰霍普金斯大学医学院的生物医学工程博士学位，在那里他获得了David Israel Macht研究卓越奖，以及罗格斯大学的生物医学工程理学硕士学位。
- Siddhartha Kadia is an experienced executive with over 20 years in the life sciences, diagnostics and biotechnology sectors. Since January 2025, Dr. Kadia has served as Chief Executive Officer of Calibre Scientific, a diversified global provider of life science reagents, tools, instruments, and other consumables to the lab research, diagnostics and biopharmaceutical communities. From March 2022 to August 2023, he served as Chief Executive Officer of PhenomeX and its predecessor Berkeley Lights until its acquisition by Bruker Corporation. From 2014 to 2018, he served as Chief Executive Officer of EAG Laboratories. From 2005 to 2014, he served in various roles at Life Technologies (formerly Invitrogen Corporation), including President of the company’s Life Sciences Division, until the company was acquired by Thermo Fisher Scientific. Dr. Kadia began his career at consultancy firm McKinsey & Company, where he worked from 2001 to 2005. Dr. Kadia holds a Ph.D. in Biomedical Engineering from Johns Hopkins University School of Medicine, where he was honored with the David Israel Macht Award for Excellence in Research, and a Masters of Science in Biomedical Engineering from Rutgers University.
- Siddhartha Kadia
-
Siddhartha Kadia，2013年3月起担任本公司董事。2014年4月起，他担任Evans Analytical Group EAG的总裁、首席执行官，这是全球领先的私营公司，为多个行业技术公司的产品开发过程提供创新的分析服务。加入EAG之前，2013年4月至2014年2月，他是Life Technologies Corporation生命科学部的总裁，这是全球性的生物技术上市公司。2011年4月至2013年4月，他担任Life Technologies Greater China的总裁，这是Life Technologies Corporation的子公司。此前，他担任过Life Technologies的多个行政职务，包括：2010年4月对2011年4月，担任Life Technologies Japan Ltd的总裁；2009年6月至2010年3月，担任其首席运营官；2008年7月至2009年6月，担任其首席营销官。2005年7月至2008年7月，他在Invitrogen Corporation担任过许多职务，最后的是全球营销与电子商务副总裁；这是一个上市的生物技术公司，在2008年与Applied Biosystems合并而成立Life Technologies。2005年加入Invitrogen Corporation之前，他是McKinsey & Company的管理顾问，专注于医疗行业的相关业务：帮助美国和欧洲的医疗器械公司制定战略方向、改善营收；为美国的地方和州级政府提供医疗支出有效性方面的咨询服务；为中大型的美国医疗保健供应商提供增强盈利方面的咨询服务。加入McKinsey之前，他是Johns Hopkins University School of Medicine的博士后研究员。
Siddhartha Kadia,has served as a member of our board of directors since 2021. Dr. Kadia currently serves on the boards of NuVasive, Inc., a medical devices company, and ALS Limited, a testing and verification services company, as well as other private biotechnology companies. Dr. Kadia also previously served on the board of Horizon Discovery Group, a biotechnology company, in 2020. From 2014 to 2018 Dr. Kadia served as president and CEO of EAG, Inc., a global scientific services company providing analytical testing and consulting solutions. Prior to his time at EAG, Inc., Dr. Kadia spent nine years with Life Technologies Corporation and its predecessor Invitrogen Corporation. Dr. Kadia held various positions with increasing responsibilities, including marketing and operations roles, as well as leadership roles in Japan and China. Most notably, he served as President, Life Sciences Division at Life Technologies where he managed a $2 billion product portfolio. Prior to Life Technologies, Dr. Kadia was a management consultant at McKinsey & Company in the Healthcare Practice, assisting global medical device companies, local and state governments, and healthcare providers. Dr. Kadia earned a B.E. in electronics and telecommunications from Gujarat University in India, an M.S. in biomedical engineering from Rutgers University, and a Ph.D. in biomedical engineering from Johns Hopkins University. - Siddhartha Kadia，2013年3月起担任本公司董事。2014年4月起，他担任Evans Analytical Group EAG的总裁、首席执行官，这是全球领先的私营公司，为多个行业技术公司的产品开发过程提供创新的分析服务。加入EAG之前，2013年4月至2014年2月，他是Life Technologies Corporation生命科学部的总裁，这是全球性的生物技术上市公司。2011年4月至2013年4月，他担任Life Technologies Greater China的总裁，这是Life Technologies Corporation的子公司。此前，他担任过Life Technologies的多个行政职务，包括：2010年4月对2011年4月，担任Life Technologies Japan Ltd的总裁；2009年6月至2010年3月，担任其首席运营官；2008年7月至2009年6月，担任其首席营销官。2005年7月至2008年7月，他在Invitrogen Corporation担任过许多职务，最后的是全球营销与电子商务副总裁；这是一个上市的生物技术公司，在2008年与Applied Biosystems合并而成立Life Technologies。2005年加入Invitrogen Corporation之前，他是McKinsey & Company的管理顾问，专注于医疗行业的相关业务：帮助美国和欧洲的医疗器械公司制定战略方向、改善营收；为美国的地方和州级政府提供医疗支出有效性方面的咨询服务；为中大型的美国医疗保健供应商提供增强盈利方面的咨询服务。加入McKinsey之前，他是Johns Hopkins University School of Medicine的博士后研究员。
- Siddhartha Kadia,has served as a member of our board of directors since 2021. Dr. Kadia currently serves on the boards of NuVasive, Inc., a medical devices company, and ALS Limited, a testing and verification services company, as well as other private biotechnology companies. Dr. Kadia also previously served on the board of Horizon Discovery Group, a biotechnology company, in 2020. From 2014 to 2018 Dr. Kadia served as president and CEO of EAG, Inc., a global scientific services company providing analytical testing and consulting solutions. Prior to his time at EAG, Inc., Dr. Kadia spent nine years with Life Technologies Corporation and its predecessor Invitrogen Corporation. Dr. Kadia held various positions with increasing responsibilities, including marketing and operations roles, as well as leadership roles in Japan and China. Most notably, he served as President, Life Sciences Division at Life Technologies where he managed a $2 billion product portfolio. Prior to Life Technologies, Dr. Kadia was a management consultant at McKinsey & Company in the Healthcare Practice, assisting global medical device companies, local and state governments, and healthcare providers. Dr. Kadia earned a B.E. in electronics and telecommunications from Gujarat University in India, an M.S. in biomedical engineering from Rutgers University, and a Ph.D. in biomedical engineering from Johns Hopkins University.
- John Sullivan
-
John Sullivan，他于2017年9月从Mesa首席执行官兼总裁的职位退休后被任命为董事会主席。Sullivan博士于2004年10月加入Mesa Laboratories, Inc.担任销售和营销副总裁，并于2009年晋升为总裁兼首席运营官。此前，Sullivan博士在Varian, Inc.（主要分析仪器制造商）担任研发、销售和营销管理以及业务开发的领导职务，并担任美国食品和药物管理局的研究科学家以及BioMed Research Labs的分析化学家。Sullivan博士于1976年获得Western Washington大学的生物学学士学位，并于1982年获得Washington大学的食品科学博士学位。
John Sullivan,was appointed Chairman of the Board upon his retirement from his position as Mesa's Chief Executive Officer and President in September 2017. Dr. Sullivan joined Mesa Laboratories, Inc. in October 2004 in the role of Vice President of Sales and Marketing and was promoted to the positions of President and Chief Operating Officer in 2009. Previously, Dr. Sullivan held leadership positions in Research and Development, Sales and Marketing Management, and Business Development at Varian, Inc., a major analytical instrument manufacturer, in addition to serving as a research scientist at the U.S. Food and Drug Administration and as an analytical chemist at BioMed Research Labs. Dr. Sullivan received his Bachelor of Science degree in Biology from Western Washington University in 1976 and a Ph.D. degree in Food Science from the University of Washington in 1982. - John Sullivan，他于2017年9月从Mesa首席执行官兼总裁的职位退休后被任命为董事会主席。Sullivan博士于2004年10月加入Mesa Laboratories, Inc.担任销售和营销副总裁，并于2009年晋升为总裁兼首席运营官。此前，Sullivan博士在Varian, Inc.（主要分析仪器制造商）担任研发、销售和营销管理以及业务开发的领导职务，并担任美国食品和药物管理局的研究科学家以及BioMed Research Labs的分析化学家。Sullivan博士于1976年获得Western Washington大学的生物学学士学位，并于1982年获得Washington大学的食品科学博士学位。
- John Sullivan,was appointed Chairman of the Board upon his retirement from his position as Mesa's Chief Executive Officer and President in September 2017. Dr. Sullivan joined Mesa Laboratories, Inc. in October 2004 in the role of Vice President of Sales and Marketing and was promoted to the positions of President and Chief Operating Officer in 2009. Previously, Dr. Sullivan held leadership positions in Research and Development, Sales and Marketing Management, and Business Development at Varian, Inc., a major analytical instrument manufacturer, in addition to serving as a research scientist at the U.S. Food and Drug Administration and as an analytical chemist at BioMed Research Labs. Dr. Sullivan received his Bachelor of Science degree in Biology from Western Washington University in 1976 and a Ph.D. degree in Food Science from the University of Washington in 1982.
高管简历
中英对照 | 中文 | 英文- Brian Archbold
Brian Archbold于2018年1月加入Mesa Labs，担任高级副总裁，持续改进。2015年1月至2018年，Archbold先生在全球医疗和汽车零部件制造商Quadion LLC担任全球运营Vice President。2012年9月至2015年1月，Archbold先生担任贝克曼库尔特（Beckman Coulter）的运营总监，该公司是丹纳赫公司的一部分。任职Danaher公司之前，他曾任职Thermo Fisher Scientific公司，在那里他曾担任多种高级领导职务，并逐步负责运营。Archbold先生的职业生涯始于IBM的供应链管理。Archbold先生拥有Central Michigan University理学学士学位和Michigan State University工商管理硕士学位。
Brian Archbold,joined Mesa in January 2018 as Senior Vice President, Continuous Improvement. From January 2015 to 2018, Mr. Archbold worked for Quadion LLC, a global manufacturer of medical and automotive components, as Vice President of Global Operations. From September 2012 to January 2015, Mr. Archbold was Director of Operations for Beckman Coulter, part of the Danaher Corporation. Prior to Danaher, Brian was with Thermo Fisher Scientific where he held various senior leadership positions of progressive responsibility in Operations. Mr. Archbold began his career with IBM in Supply Chain Management. Mr. Archbold has a Bachelor of Science degree from Central Michigan University and his MBA from Michigan State University.- Brian Archbold于2018年1月加入Mesa Labs，担任高级副总裁，持续改进。2015年1月至2018年，Archbold先生在全球医疗和汽车零部件制造商Quadion LLC担任全球运营Vice President。2012年9月至2015年1月，Archbold先生担任贝克曼库尔特（Beckman Coulter）的运营总监，该公司是丹纳赫公司的一部分。任职Danaher公司之前，他曾任职Thermo Fisher Scientific公司，在那里他曾担任多种高级领导职务，并逐步负责运营。Archbold先生的职业生涯始于IBM的供应链管理。Archbold先生拥有Central Michigan University理学学士学位和Michigan State University工商管理硕士学位。
- Brian Archbold,joined Mesa in January 2018 as Senior Vice President, Continuous Improvement. From January 2015 to 2018, Mr. Archbold worked for Quadion LLC, a global manufacturer of medical and automotive components, as Vice President of Global Operations. From September 2012 to January 2015, Mr. Archbold was Director of Operations for Beckman Coulter, part of the Danaher Corporation. Prior to Danaher, Brian was with Thermo Fisher Scientific where he held various senior leadership positions of progressive responsibility in Operations. Mr. Archbold began his career with IBM in Supply Chain Management. Mr. Archbold has a Bachelor of Science degree from Central Michigan University and his MBA from Michigan State University.
- Siddhartha Kadia
Siddhartha Kadia是一位经验丰富的高管，在生命科学、诊断和生物技术领域拥有超过20年的经验。自2025年1月起，Kadia博士担任Calibre Scientific的首席执行官，Calibre Scientific是一家为实验室研究、诊断和生物制药界提供生命科学试剂、工具、仪器和其他耗材的多元化全球供应商。2022年3月至2023年8月，担任PhenomeX及其前身Berkeley Lights的首席执行官，直至其被Bruker Corporation收购。2014年至2018年，任EAG实验室首席执行官。2005年至2014年，他曾在Life Technologies（前身为Invitrogen Corporation）担任多个职务，包括该公司生命科学部门总裁，直到该公司被赛默飞世尔收购。Kadia博士的职业生涯始于咨询公司麦肯锡公司，他曾于2001年至2005年在该公司工作。Kadia博士拥有约翰霍普金斯大学医学院的生物医学工程博士学位，在那里他获得了David Israel Macht研究卓越奖，以及罗格斯大学的生物医学工程理学硕士学位。
Siddhartha Kadia is an experienced executive with over 20 years in the life sciences, diagnostics and biotechnology sectors. Since January 2025, Dr. Kadia has served as Chief Executive Officer of Calibre Scientific, a diversified global provider of life science reagents, tools, instruments, and other consumables to the lab research, diagnostics and biopharmaceutical communities. From March 2022 to August 2023, he served as Chief Executive Officer of PhenomeX and its predecessor Berkeley Lights until its acquisition by Bruker Corporation. From 2014 to 2018, he served as Chief Executive Officer of EAG Laboratories. From 2005 to 2014, he served in various roles at Life Technologies (formerly Invitrogen Corporation), including President of the company’s Life Sciences Division, until the company was acquired by Thermo Fisher Scientific. Dr. Kadia began his career at consultancy firm McKinsey & Company, where he worked from 2001 to 2005. Dr. Kadia holds a Ph.D. in Biomedical Engineering from Johns Hopkins University School of Medicine, where he was honored with the David Israel Macht Award for Excellence in Research, and a Masters of Science in Biomedical Engineering from Rutgers University.- Siddhartha Kadia是一位经验丰富的高管，在生命科学、诊断和生物技术领域拥有超过20年的经验。自2025年1月起，Kadia博士担任Calibre Scientific的首席执行官，Calibre Scientific是一家为实验室研究、诊断和生物制药界提供生命科学试剂、工具、仪器和其他耗材的多元化全球供应商。2022年3月至2023年8月，担任PhenomeX及其前身Berkeley Lights的首席执行官，直至其被Bruker Corporation收购。2014年至2018年，任EAG实验室首席执行官。2005年至2014年，他曾在Life Technologies（前身为Invitrogen Corporation）担任多个职务，包括该公司生命科学部门总裁，直到该公司被赛默飞世尔收购。Kadia博士的职业生涯始于咨询公司麦肯锡公司，他曾于2001年至2005年在该公司工作。Kadia博士拥有约翰霍普金斯大学医学院的生物医学工程博士学位，在那里他获得了David Israel Macht研究卓越奖，以及罗格斯大学的生物医学工程理学硕士学位。
- Siddhartha Kadia is an experienced executive with over 20 years in the life sciences, diagnostics and biotechnology sectors. Since January 2025, Dr. Kadia has served as Chief Executive Officer of Calibre Scientific, a diversified global provider of life science reagents, tools, instruments, and other consumables to the lab research, diagnostics and biopharmaceutical communities. From March 2022 to August 2023, he served as Chief Executive Officer of PhenomeX and its predecessor Berkeley Lights until its acquisition by Bruker Corporation. From 2014 to 2018, he served as Chief Executive Officer of EAG Laboratories. From 2005 to 2014, he served in various roles at Life Technologies (formerly Invitrogen Corporation), including President of the company’s Life Sciences Division, until the company was acquired by Thermo Fisher Scientific. Dr. Kadia began his career at consultancy firm McKinsey & Company, where he worked from 2001 to 2005. Dr. Kadia holds a Ph.D. in Biomedical Engineering from Johns Hopkins University School of Medicine, where he was honored with the David Israel Macht Award for Excellence in Research, and a Masters of Science in Biomedical Engineering from Rutgers University.
- Siddhartha Kadia
Siddhartha Kadia，2013年3月起担任本公司董事。2014年4月起，他担任Evans Analytical Group EAG的总裁、首席执行官，这是全球领先的私营公司，为多个行业技术公司的产品开发过程提供创新的分析服务。加入EAG之前，2013年4月至2014年2月，他是Life Technologies Corporation生命科学部的总裁，这是全球性的生物技术上市公司。2011年4月至2013年4月，他担任Life Technologies Greater China的总裁，这是Life Technologies Corporation的子公司。此前，他担任过Life Technologies的多个行政职务，包括：2010年4月对2011年4月，担任Life Technologies Japan Ltd的总裁；2009年6月至2010年3月，担任其首席运营官；2008年7月至2009年6月，担任其首席营销官。2005年7月至2008年7月，他在Invitrogen Corporation担任过许多职务，最后的是全球营销与电子商务副总裁；这是一个上市的生物技术公司，在2008年与Applied Biosystems合并而成立Life Technologies。2005年加入Invitrogen Corporation之前，他是McKinsey & Company的管理顾问，专注于医疗行业的相关业务：帮助美国和欧洲的医疗器械公司制定战略方向、改善营收；为美国的地方和州级政府提供医疗支出有效性方面的咨询服务；为中大型的美国医疗保健供应商提供增强盈利方面的咨询服务。加入McKinsey之前，他是Johns Hopkins University School of Medicine的博士后研究员。
Siddhartha Kadia,has served as a member of our board of directors since 2021. Dr. Kadia currently serves on the boards of NuVasive, Inc., a medical devices company, and ALS Limited, a testing and verification services company, as well as other private biotechnology companies. Dr. Kadia also previously served on the board of Horizon Discovery Group, a biotechnology company, in 2020. From 2014 to 2018 Dr. Kadia served as president and CEO of EAG, Inc., a global scientific services company providing analytical testing and consulting solutions. Prior to his time at EAG, Inc., Dr. Kadia spent nine years with Life Technologies Corporation and its predecessor Invitrogen Corporation. Dr. Kadia held various positions with increasing responsibilities, including marketing and operations roles, as well as leadership roles in Japan and China. Most notably, he served as President, Life Sciences Division at Life Technologies where he managed a $2 billion product portfolio. Prior to Life Technologies, Dr. Kadia was a management consultant at McKinsey & Company in the Healthcare Practice, assisting global medical device companies, local and state governments, and healthcare providers. Dr. Kadia earned a B.E. in electronics and telecommunications from Gujarat University in India, an M.S. in biomedical engineering from Rutgers University, and a Ph.D. in biomedical engineering from Johns Hopkins University.- Siddhartha Kadia，2013年3月起担任本公司董事。2014年4月起，他担任Evans Analytical Group EAG的总裁、首席执行官，这是全球领先的私营公司，为多个行业技术公司的产品开发过程提供创新的分析服务。加入EAG之前，2013年4月至2014年2月，他是Life Technologies Corporation生命科学部的总裁，这是全球性的生物技术上市公司。2011年4月至2013年4月，他担任Life Technologies Greater China的总裁，这是Life Technologies Corporation的子公司。此前，他担任过Life Technologies的多个行政职务，包括：2010年4月对2011年4月，担任Life Technologies Japan Ltd的总裁；2009年6月至2010年3月，担任其首席运营官；2008年7月至2009年6月，担任其首席营销官。2005年7月至2008年7月，他在Invitrogen Corporation担任过许多职务，最后的是全球营销与电子商务副总裁；这是一个上市的生物技术公司，在2008年与Applied Biosystems合并而成立Life Technologies。2005年加入Invitrogen Corporation之前，他是McKinsey & Company的管理顾问，专注于医疗行业的相关业务：帮助美国和欧洲的医疗器械公司制定战略方向、改善营收；为美国的地方和州级政府提供医疗支出有效性方面的咨询服务；为中大型的美国医疗保健供应商提供增强盈利方面的咨询服务。加入McKinsey之前，他是Johns Hopkins University School of Medicine的博士后研究员。
- Siddhartha Kadia,has served as a member of our board of directors since 2021. Dr. Kadia currently serves on the boards of NuVasive, Inc., a medical devices company, and ALS Limited, a testing and verification services company, as well as other private biotechnology companies. Dr. Kadia also previously served on the board of Horizon Discovery Group, a biotechnology company, in 2020. From 2014 to 2018 Dr. Kadia served as president and CEO of EAG, Inc., a global scientific services company providing analytical testing and consulting solutions. Prior to his time at EAG, Inc., Dr. Kadia spent nine years with Life Technologies Corporation and its predecessor Invitrogen Corporation. Dr. Kadia held various positions with increasing responsibilities, including marketing and operations roles, as well as leadership roles in Japan and China. Most notably, he served as President, Life Sciences Division at Life Technologies where he managed a $2 billion product portfolio. Prior to Life Technologies, Dr. Kadia was a management consultant at McKinsey & Company in the Healthcare Practice, assisting global medical device companies, local and state governments, and healthcare providers. Dr. Kadia earned a B.E. in electronics and telecommunications from Gujarat University in India, an M.S. in biomedical engineering from Rutgers University, and a Ph.D. in biomedical engineering from Johns Hopkins University.
- John V. Sakys
John V. Sakys， 2012年10月加入Mesa担任首席财务官。从2009年到2012年10月，他在The Berry Company, LLC及其前身公司Local Insight Regatta Holdings, Inc.担任多个职位，最近担任其副总裁兼首席会计官。2001年至2009年，Sakys先生担任Isonics Corporation（总部位于丹佛地区的前纳斯达克上市公司）的副总裁兼首席财务官。从2000年9月到2001年4月，Sakys先生担任AuraServ Communications的财务总监。1998年7月至2000年9月，Sakys先生担任Media One, Inc.的财务报告总监。1994年12月至1998年7月，他是Ernst and Young LLP的审计经理。他于1990年获得加州大学圣巴巴拉分校（University of California at Santa Barbara）的商业经济学学士学位，主修会计，是一名注册会计师。
John V. Sakys,joined Mesa in October 2012 as Chief Financial Officer. From 2009 through October 2012, Mr. Sakys held several positions with The Berry Company, LLC, and its predecessor company, Local Insight Regatta Holdings, Inc., most recently as its Vice President and Chief Accounting Officer. From 2001 to 2009, Mr. Sakys was the Vice President and Chief Financial Officer of Isonics Corporation, a former Nasdaq listed company based in the Denver area. From September 2000 to April 2001, Mr. Sakys was Controller of AuraServ Communications. From July 1998 to September 2000, Mr. Sakys was Director of Financial Reporting for Media One, Inc. From December 1994 to July 1998, Mr. Sakys was an audit manager at Ernst and Young LLP. Mr. Sakys received his Bachelor of Arts degree in Business Economics with an emphasis in accounting from the University of California at Santa Barbara in 1990 and is a Certified Public Accountant.- John V. Sakys， 2012年10月加入Mesa担任首席财务官。从2009年到2012年10月，他在The Berry Company, LLC及其前身公司Local Insight Regatta Holdings, Inc.担任多个职位，最近担任其副总裁兼首席会计官。2001年至2009年，Sakys先生担任Isonics Corporation（总部位于丹佛地区的前纳斯达克上市公司）的副总裁兼首席财务官。从2000年9月到2001年4月，Sakys先生担任AuraServ Communications的财务总监。1998年7月至2000年9月，Sakys先生担任Media One, Inc.的财务报告总监。1994年12月至1998年7月，他是Ernst and Young LLP的审计经理。他于1990年获得加州大学圣巴巴拉分校（University of California at Santa Barbara）的商业经济学学士学位，主修会计，是一名注册会计师。
- John V. Sakys,joined Mesa in October 2012 as Chief Financial Officer. From 2009 through October 2012, Mr. Sakys held several positions with The Berry Company, LLC, and its predecessor company, Local Insight Regatta Holdings, Inc., most recently as its Vice President and Chief Accounting Officer. From 2001 to 2009, Mr. Sakys was the Vice President and Chief Financial Officer of Isonics Corporation, a former Nasdaq listed company based in the Denver area. From September 2000 to April 2001, Mr. Sakys was Controller of AuraServ Communications. From July 1998 to September 2000, Mr. Sakys was Director of Financial Reporting for Media One, Inc. From December 1994 to July 1998, Mr. Sakys was an audit manager at Ernst and Young LLP. Mr. Sakys received his Bachelor of Arts degree in Business Economics with an emphasis in accounting from the University of California at Santa Barbara in 1990 and is a Certified Public Accountant.